
KPV is a tripeptide (H-Lys-Pro-Val-OH) representing the C-terminal 11-13 fragment of α-melanocyte-stimulating hormone (α-MSH). It retains much of the anti-inflammatory pathway activity of the parent molecule without the pigmentary effects associated with N-terminal melanocortin receptor binding.
Published studies describe KPV inhibiting NF-κB nuclear translocation, reducing pro-inflammatory cytokine output (TNF-α, IL-1β, IL-6) in activated immune cells, and influencing intestinal epithelial barrier integrity through tight junction protein expression.
Identified as the smallest active fragment of α-MSH during structure-activity research in the 1990s and early 2000s. Continues to appear in inflammation and mucosal biology literature.
Published research literature covers the following areas:
LAR supplies this compound as a reference standard to qualified laboratories. No dosing schedules, administration methods, or human-use guidance is provided or implied.
Sealed vial: Stable at refrigerated temperatures (2–8 °C) for up to 24 months. Stable at room temperature (up to 25 °C) for 30 days during shipping.
After opening: Refrigerate at 2–8 °C and use within 30 days. Protect from light. Do not freeze after opening.
Visual check: Solution should remain clear. Discard if discoloration or precipitate appears.
Every batch is independently tested for purity, mass, and endotoxin load. Click any report to view the full analysis.
No. Research peptides supplied by LAR are reference materials for laboratory investigation. They are not approved by the FDA or any national regulatory body for human use.
Yes. Vials ship as lyophilized powder, giving your lab control over solvent selection and final concentration. Reconstitution should follow your laboratory's standard practice.
Each manufacturing batch is tested by an independent third-party laboratory using HPLC-UV analysis. The full report, including chromatogram and mass spectrometry, is available above.
Orders ship within 1–2 business days via discreet packaging.